Lili Wang, M.D., Ph.D.

626-218-5628
Lili Wang, M.D., Ph.D.
Professor, Department of Systems Biology
Research Area
  • Genetic Alterations and CLL Biology
  • RNA Splicing Dysregulation and Oncogenesis
Lili Wang, M.D., Ph.D., is a Professor in the Department of Systems Biology. 
 
Dr. Wang obtained her M.D. at the China Medical University (Shenyang, China) and her Ph.D. degree at the Tokai University (Isehara, Japan).  She received her postdoctoral training at the University of Illinois (Chicago, IL) and Dana-Farber Cancer Institute/Harvard Medical School (Boston, MA). In 2017, Dr. Wang joined the Department of Systems Biology at the Beckman Research Institute. She is also a member of the Toni Stephenson Lymphoma Center at City of Hope. 
 
Dr. Wang’s group studies genetic alterations, RNA splicing dysregulation and oncogenesis in hematologic malignancies. The laboratory focuses on understanding how splicing factor mutations and RNA epigenetics dysregulation contributing to splicing dysregulation and lymphoma biology with chronic lymphocytic leukemia and mantle cell lymphoma as disease models. The ultimate goal is to discover novel prognostic markers and to design better therapeutic approaches.
 

Location

Education & Experience

Degrees

  • 2003, Ph.D., Immunology, Tokai University

  • 1998, MS, Immunology, China Medical University

  • 1994, M.D., China Medical University

Fellowship

  • 2003-2008, Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL

  • 2008-2013, Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Professional Experience

  • 2023-present, Professor, Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA

  • 2017-2023, Associate Professor, Department of Systems Biology, Beckman Research Institute of City of Hope, Duarte, CA

  • 2013-2017, Instructor, Division of Hematologic Neoplasia, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Publications

  • Iyer P, Zhang B, Liu T, Jin M, Hart K, Zhang J, Siegert V, Remke M, Wang X, Yu L, Song J, Venkataraman G, Chan WC, Jia Z, Buchner M, Siddiqi T, Rosen ST, Danilov A, Wang L. MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOS. Sci Transl Med. 2024.
  • Cusan M, Shen H, Zhang B, Liao A, Yang L, Jin M, Fernandez M, Iyer P, Wu Y, Hart K, Gutierrez C, Nik S, Pruett-Miller SM, Stark J, Obeng E, Bowman TV, Wu CJ, Lin RJ, Wang L. SF3B1 mutation and ATM deletion co-drive leukemogenesis via centromeric R-loop dysregulation. J Clin Invest 2023.
  • Wu Y, Jin M, Fernandez M, Fernandez M, Hart KL, Liao A, Ge X, Fernandes SM, McDonald T, Chen Z, Röth D, Ghoda LY, Marcucci G, Kalkum M, Pillai RK, Danilov AV, Li JJ, Chen J, Brown JR, Rosen ST, Siddiqi T, Wang L. METTL3-mediated m6A modification controls splicing factor abundance and contributes to aggressive CLL. Blood Cancer Discov. 2023 4(3):228-245. PMCID: 37067905.
  • Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, Yang L, Gine E, Clot G, Chen L, Yu Y, Zou D, Wang J, Phan A, Cui R, Li F, Sun Q, Zhai Q, Wang T, Yu Z, Liu L, Liu W, Lyv R, Sui W, Huang W, Xiong W, Wang H, Li C, Xiao Z, Hao M, Wang J, Chen gT, Bea S, Herrera A, Danilov A, Campo E, Ngo V, Qiu L, Wang L. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Invest 2022. Feb 1; 132(3). PMCID: 8803323.
  • Yin S, Gambe R, Sun, J, Martinez, AZ, Cartun JZ, Regis, F, Wan Y, Fan, J, Brooks, AN, Herman SE, ten Hacken E, Taylor-Weiner, A, Rassenti L, Ghia EM, Kipps TJ, Obeng EA, Cibulaskis C, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of Sf3b1 mutation and Atm deletion. Cancer Cell 2019 35(2):283-296.
  • Wang L, Fan J, Francis J, Zhang C, Herger S, Gambe R, Li S, Zhou C, Yang C, Xiao S, Dal Cin P, Bowden M, Kotliar D, Shukla S, Brown JR, Neuberg D, Livak KJ, Kharchenko PV, Wu CJ. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. Genome Res 2017 27 1-13
  • Wang L, Brooks AL, Fan J, Wan Y, Gambe R, Li S, Hergert S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassent LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla S, Aster JC, Reed R, DeLuca DS, Brown JR, Neuberg D, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. Cancer Cell. 2016 30(5): 750-763.

  • Wang L, Shalek AK, Lawrence MS, Gaublomme JT, Pochet N, Stojanov P, Sougnez C, Stevenson K, Neuberg D, Cibulskis K, Zhang W, Sievers QL, Vartanov AR, Goldstein NR, Sutton A, Van de Peer Y, Gabriel S, He X, Lander ES, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ. Somatic mutation as a mechanism of Wnt/β-catenin pathway activation in CLL. Blood 2014 124(7):1089-98. PMC4133483

    Read at PubMed

  • Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, Deluca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med, 2011 365(26):2497-506. PMC3685413